| 61/237 | US=60 / Biol/Mol Karna P, Yang L. Apoptotic signaling pathway and resistance to apoptosis in breast cancer stem cells. In: Chen GG, Lai PBS. Apoptosis in carcinogenesis and chemotherapy: apoptosis in cancer. New York: Springer, 2009. p. 1-23. ISBN 978-1-4020-9596-2. RESISTENCIA A APOPTOSE; CELULAS TRONCO EM NEOPLASIAS DE MAMA; TERAPIA DE ALVO MOLECULAR; VIA APOPTOTICA; MECANISMOS DE RESISTENCIA A APOPTOSE |
| 62/237 | US=64 / Biol/Mol Weissig V, D´Souza GGM, Cheng SM, Boddapati S. Mitochondrial nanotechnology for cancer therapy. In: Singh KK, Costello LC. Mitochondria and cancer. New York: Spriger, 2009. p. 265-79. ISBN 978-0-387-84834-1. NANOTECNOLOGIA MITOCONDRIAL PARA TERAPIA DE CANCER; NANOTECNOLOGIA E TERAPIA DO CANCER; BARREIRAS CITOSOLICOS PARA A ENTREGA DA DROGA MITOCONDRIAL; MITOCONDRIAS-ALVO SISTEMAS DE ENTREGA NANODRUG; NANOPARTICULAS DE OURO ADEQUADO PARA A MITOCONDRIA |
| 63/237 | US=97 / Biol/Mol Song S, Dent P, Grant S. The impact of molecularly targeted in multi-modality therapy. In: Molls M, Vaupel P, Nieder C, Anscher MS. The impact of tumor biology on cancer treatment and multidisciplinary strategies. Baltimore: Springer, 2009. p. 191-219. (Medical Radiology Radiation Oncology) ISBN 978-3-540-74385-9. CANCER; MULTI-TERAPIA; CLASSES DE AGENTES DE TERAPIA ESPECIFICA; TERAPIA-ALVO DE MALIGNIDADES COMUNS; RADIACAO; TERAPIA-ALVO; TERAPIAS CONVENCIONAIS |
| 64/237 | US=97 / Biol/Mol Nieder C, Mehta MP. Dose-escalated high-precision radiotherapy: a method to overcome variations in biology and radiosensitivity the success of conventional approaches?. In: Molls M, Vaupel P, Nieder C, Anscher MS. The impact of tumor biology on cancer treatment and multidisciplinary strategies. Baltimore: Springer, 2009. p. 335-46. (Medical Radiology Radiation Oncology) ISBN 978-3-540-74385-9. RADIOTERAPIA; RADIOSSENSIBILIDADE; ESTADIAMENTO; DELIMITACAO DE VOLUME-ALVO |
| 65/237 | US=49-G / Câncer Cuevas H, Boudreau N. Managing tumor angiogenesis: lessons from VEGF-resistant tumors and wounds. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2009. p. 25-42. ISBN 978-0-12-3747730. GERENCIANDO ANGIOGENESE TUMORAL; LICOES DE VEGF-RESISTENTES TUMORES E FERIDAS; ANGIOGENESE; VEGF E ANGIOGENESE TUMORAL; VEGF E RECRUTAMENTO DE EPC NA ANGIOGENESE TUMORAL; LIMITACOES NO ALVO VEGF |
| 66/237 | US=49-G / Câncer Rahman M, Pumphrey JG, Lipkowitz S. The TRAIL to targeted therapy of breast cancer. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2009. p. 43-73. ISBN 978-0-12-3747730. TRIAL PARA TERAPIA-ALVO DO CANCER DE MAMA; TRIAL E RECEPTORES; APOPTOSE INDUZIDA POR TRAIL EM CELULAS DE CANCER DE MAMA; SUPERAR A RESISTENCIA TRAIL |
| 67/237 | US=10 / Gastro Scartozzi M, Pierantoni C, Pagliacci A, Cascinu S. Chemotherapy and radiotherapy in pancreatic cancer. In: Siquini W, editor. Surgical treatment of pancreatic diseases. New York: Springer, 2008. p. 481-500. ISBN 978-88-470-0855-7. RADIOTERAPIA EM CANCER DE PANCREAS; QUIMIOTERAPIA; NEOADJUVANTE PARA CANCER DE PANCREAS. TRATAMENTO ADJUVANTE; QUIMIORADIOTERAPIA NA DOENCA LOCALMENTE AVANCADA; QUIMIOTERAPIA NA DOENCA AVANCADA; TERAPIA-ALVO EM CANCER DE PANCREAS AVANCADO |
| 68/237 | US=103 / Câncer Zografos GC, Michalopoulos NV, Zagouri F. Hormone therapies. In: Missailidis S. Anticancer therapeutics. New Jersey: Wiley Blackwell, 2008. p. 159-86. ISBN 978-0-470-72303-6. TERAPIA HORMONAL; TERAPIA ALVO; RECEPTOR DE ESTROGENIO; TERAPIA GUIADA POR PROGESTERONA; TUMORES NEUROENDOCRINOS |
| 69/237 | US=103 / Câncer Bradshaw TD. Target-directed drug discovery. In: Missailidis S. Anticancer therapeutics. New Jersey: Wiley Blackwell, 2008. p. 223-43. ISBN 978-0-470-72303-6. TERAPIA ALVO-DIRIGIDA; TIROSINA-QUINASES; CANCER DE PULMAO DE CELULAS NAO PEQUENAS; LEUCEMIA MIELOIDE CRONICA; CANCER DE MAMA; ANGIOGENESE; CICLO CELULAR; APOPTOSE; MTOR |
| 70/237 | US=110 / Câncer Murgo AJ, Kummar S, Gutierrez M, Tomaszewski JE, Doroshow JH. Principles of molecularly targeted therapy: present and future. In: Abeloff MD. Abeloff's clinical oncology. 4th ed. Philadelphia: Churchill Livingstone, 2008. p. 485-500. ISBN 978-0-443-06695-5. CANCER; TERAPIA ALVO MOLECULAR; ALVOS MOLECULARES; AGENTES ANTICANCERIGENOS; IMAGEM FUNCIONAL; IMAGEM MOLECULAR; SELECAO DO PACIENTE |
| 71/237 | US=29-E / Enfermagem Bonassa EMA, Mota MLS, Gato MIR. Terapia antineoplásica. In: Bonassa EMA, Gato MIR. Terapêutica oncológica para enfermeiros e farmacêuticos. 4ª ed. São Paulo: Atheneu, 2012. p. 17-24. ISBN 85-388-0284-6. QUIMIOTERAPIA ANTINEOPLASICA; AGENTES ANTINEOPLASICOS; AGENTES ALQUILANTES; COMPOSTOS DE PLATINA; AGENTES ANTIMETABOLITOS; ANTIBIOTICOS ANTITUMORAIS; DERIVADOS VEGETAIS; ANALOGOS DE CAMPTOTECINA; AGENTES CITOTOXICOS; TERAPIA HORMONAL; TERAPIA BIOLOGICO; IMUNOTERAPIA; FATORES DE CRESCIMENTO HEMATOPOETICO; TERAPIA-ALVO MOLECULAR; RETINOIDES; TERAPIA FOTODINAMICA; QUIMIOPREVENCAO; AGENTES ANTINEOPLASICOS. DESCRICAO |
| 72/237 | US=15 / Gastro Melstrom LG, Grippo PJ. Models of pancreatic cancer: understanding disease progression. In: Lowy AM, Leach SD, Philip PA. Pancreatic cancer. New York: Springer, 2008. p. 137-58. ISBN 978-0-387-69250-0. MODELOS DE CANCER DE PANCREAS; PROGRESSAO DA DOENCA; PANCREATICAS CELULAS CANCERIGENAS EM CULTURA; MODELO ORTOTOPICO; ELASTASE ALVO |
| 73/237 | US=15 / Gastro El-Rayes B. An overview of clinical trials of targeted therapies in pancreatic cancer. In: Lowy AM, Leach SD, Philip PA. Pancreatic cancer. New York: Springer, 2008. p. 565-75. ISBN 978-0-387-69250-0. TERAPIAS-ALVO. CANCER DE PANCREAS; INIBIDORES DE PROTEASSOMA; INIBIDORES DA ANGIOGENESE; RAS INIBIDORES |
| 74/237 | US=28 / Biol/Mol Teicher BA. Newer vascular targets. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 133-53. ISBN 978-1-58829-870-6. MAIS RECENTES ALVOS VASCULARES; SAGE; ENDOSSIALINA; TEM; ANGIOGENESE ANTI; VASCULAR ALVO; GENE-EXPRESSAO ANALISE |
| 75/237 | US=28 / Biol/Mol Gordon MS, Ebbinghaus SW. Antiangiogenic therapy of renal cell carcinoma. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 427-39. ISBN 978-1-58829-870-6. CARCINOMA DE CELULAS RENAIS; CANCER DE RIM; ANTI ANGIOGENICA; TERAPIA-ALVO |
| 76/237 | US=23 / Câncer Frasci G, D'Aiuto G, Iodice G, D'Aiuto M, Comella G. Locally advanced breast cancer: role of chemotherapy in improving prognosis. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: breast carcinoma. v.1. New York: Springer, 2008. p. 327-49. ISBN 978-1-4020-8368-6. CANCER DE MAMA; CANCER DE MAMA LOCALMENTE AVANCADO; QUIMIOTERAPIA; QUIMIOTERAPIA PRE-OPERATORIA; QUIMIOTERAPIA POS-OPERATORIA; TRATAMENTO NEOADJUVANTE; TERAPIA-ALVO |
| 77/237 | US=23 / Câncer Erban JK, Lau J. Systemic therapy for breast cancer: using toxicity data to inform decisions. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: breast carcinoma. v.1. New York: Springer, 2008. p. 373-94. ISBN 978-1-4020-8368-6. CANCER DE MAMA; TERAPIA SISTEMICA; DADOS DE TOXICIDADE; TERAPIA HORMONAL; QUIMIOTERAPIA; TERAPIAS-ALVO; TOXICIDADE AGUDA; SEQUELAS |
| 78/237 | US=23 / Câncer Shackney SE, Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA. Breast cancer: expression of HER-2 and epidermal growth factor receptor as clinical markers for response to targeted therapy. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: breast carcinoma. v.1. New York: Springer, 2008. p. 459-82. ISBN 978-1-4020-8368-6. CANCER DE MAMA; EXPRESSAO DO RECEPTOR HER-2; FATOR DE CRESCIMENTO EPIDERMICO; RESPOSTA A TERAPIA-ALVO; IMUNOHISTOQUIMICA; HIBRIDACAO IN SITU FLUORESCENTE |
| 79/237 | US=35 / Biol/Mol Mendelsohn J, Powis G. From bench to bedside with targeted therapies. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 521-30. ISBN 978-1-4160-3703-3. |
| 80/237 | US=35 / Biol/Mol Shoemaker RH, Sausville EA. Screening strategies for targeted therapeutics. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 531-8. ISBN 978-1-4160-3703-3. |